Advancing Asia’s leadership in nucleic acid and peptide therapeutics: From discovery to commercialization
Where science, innovation, and partnerships converge in China to transform next-generation modalities
Driving China's next wave of therapeutic innovation
Join China's premier gathering for nucleic acid and peptide therapeutics community connecting with domestic innovators, global partners, and regulatory experts advancing mRNA, siRNA, ASOs, RNA editing, peptides, peptide-drug conjugates, and next-gen oral peptides within China's rapidly evolving biopharma landscape.
Proven pedigree
Built on the success of RNA Leaders and TIDES, this summit brings world-class content and unparalleled networking to China's biotech hub.
Connect with China's innovation
Ecosystem Engage directly with leading Chinese biotech companies, research institutions, CDMOs, and investors driving breakthrough discoveries in mRNA, siRNA, peptide conjugates, and emerging RNA modalities.
Accelerate China market entry & expansion
Navigate China's regulatory pathways, manufacturing requirements, and commercialization strategies specific to nucleic acid and peptide therapeutics with insights from NMPA experts and successful market entrants.
Bridge innovation with global opportunities
Forge strategic partnerships between regional innovators and international pharma, technology providers, and investors seeking access to cutting-edge nucleic acid and peptide platforms. Forge meaningful connections that translate into collaborations, partnerships, and commercial opportunities in one of the world's fastest-growing markets.
Why China? Why Now?
China’s biopharma landscape is rapidly advancing across oligonucleotides, peptides, mRNA therapeutics, genome editing, and drug delivery. With extensive Asian CDMO presence and a strong supply chain from raw materials to finished products, the region is poised to accelerate the translation of next‑generation modalities from discovery to commercialization.
A comprehensive, integrated portfolio spanning North America, Europe, and Asia‑Pacific, bringing together leading scientists, biotechs, pharma, investors, and manufacturing partners to drive real‑world impact. China's nucleic acids and peptides sector is experiencing unprecedented growth.
Comprehensive programming tailored for China's therapeutic development landscape
Discover China's RNA therapeutics innovation and navigate the peptide therapeutic ecosystem from discovery to market.
Nucleic acid therapeutics track
- Discover how companies and research institutions are leveraging nucleic acid platforms to address rare diseases prevalent in Asian populations, with focus on regulatory pathways and patient access strategies.
- Examine growing capabilities in mRNA vaccine development for oncology, featuring case studies from biotech leaders and strategies for clinical translation within evolving regulatory frameworks.
- Master nucleic acid therapeutic design principles with emphasis on delivery technologies, including lipid nanoparticles and novel formulation approaches.
- Learn from experts on streamlining siRNA and ASO development, addressing manufacturing capabilities, supply chain considerations, and clinical development strategies.
- Explore expanding mRNA manufacturing infrastructure, quality control standards, and strategies for scaling production to meet demand and export opportunities.
- Discover emerging RNA editing technologies and epigenetic approaches being pioneered by research institutions and biotech companies.
Peptide therapeutics track
- Explore innovative peptide-based cancer therapies targeting high-prevalence cancers, with insights on combination strategies and regulatory approval pathways.
- Examine breakthrough peptide therapies addressing diabetes and obesity, with focus on market access and reimbursement strategies.
- Master advanced peptide design approaches with perspectives from leading research institutions and biotech companies, including AI-driven discovery platforms.
- Navigate NMPA requirements, clinical trial design considerations, and biomarker strategies specific to peptide therapeutic development, with case studies from successful programs.
- Discover innovative oral peptide delivery technologies addressing formulation challenges and manufacturing scalability.
- Address CMC requirements, analytical method development, and process optimization leveraging expanding peptide CDMO capabilities.
- Explore advances in peptide-drug conjugate platforms, combining strengths in peptide chemistry with targeted payload delivery for precision oncology.
China’s nucleic acid & peptide momentum: Where innovation meets manufacturing
Explore the key themes shaping Nucleic Acids & Peptide Summit 2026, designed to help you transform next-generation modalities.
Where science meets market opportunity
- Innovation-driven programming across oligonucleotides, peptides, mRNA, genome editing, and delivery—supported by cutting-edge RNA science, platforms, and translational research.
- Comprehensive CMC, analytical, manufacturing, and regulatory strategies covering both drug substance and drug product, enabling scale, quality, and compliance.
- Investment and partnering focus - connecting biotechs with venture capital and pharma through networking, targeted one-on-one sessions, and collaborative exchanges.
- Full supply chain representation, from raw materials and reagents to CDMOs, equipment, and analytical services, ensuring end-to-end development and manufacturing readiness. Gain a competitive advantage by uncovering what global investors and big pharma seek in cell and gene therapy products and enabling technologies to secure your next opportunity
Next-gen modalities in development
- Peptide therapeutics, oligonucleotide therapeutics, and mRNA therapeutics advancing from discovery through preclinical and clinical development.
- Genome editing and advanced conjugat delivery systems driving precision and efficacy across therapeutic programs.
- Manufacturing strategies and regulatory pathways supporting global advancement from development to commercialization.
- Clinical updates and chemistry advances showcasing progress across long and small RNA applications. Discover cutting-edge R&D developments including, in vivo CAR-T, solid tumours, and new therapeutic modalities expanding treatments to broader populations
Program spotlight
- Educational depth: Pre-conference workshops, multi-track sessions, keynote presentations addressing industry bottlenecks, immersive workshops, and research showcases.
- Networking at scale: Exhibition halls with 90+ exhibitors, focused interactions, cross-industry innovation exchange, dynamic scientific discussions, and personalized partnering.
- Technology and manufacturing excellence: Advanced drug delivery platforms, comprehensive CMC solutions, analytical rigor, and large-scale manufacturing insights.
- Cross-regional collaboration: Knowledge exchange and partnerships bridging Asia-Pacific, European, and North American markets to accelerate development and market entry. Explore effective strategies to move from clinical development to market launch
Who should attend?
Built for the nucleic acid and peptide therapeutics community
Biotech & pharma leaders
- CEOs, CSOs & R&D directors developing nucleic acid and peptide therapeutic platforms Founder
International companies seeking partnerships business development
- regulatory, and commercial leaders evaluating partnerships, licensing opportunities, and market entry strategies
Research institution leaders
- principal investigators and translational researchers advancing early-stage programs
CDMO & manufacturing partners
- Process development and manufacturing leaders from CDMOs supporting nucleic acid and peptide production Manufacturing & Operations
Regulatory & quality professionals
- Regulatory strategists and quality leaders ensuring compliance with national and international standards
Investors & business development
- VCs, corporate venture groups, and BD professionals evaluating partnership and investment opportunities in nucleic acid and peptide sectors